<DOC>
	<DOC>NCT00995345</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of KRP-104 on glycemic control in patients with type 2 diabetes inadequately controlled on metformin alone.</brief_summary>
	<brief_title>Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients meeting the following criteria at the screening visit (Visit 1) will be eligible to participate in the trial: 1. Signed written informed consent; 2. Males and females 18 to 75 years of age, inclusive; 3. Females of childbearing potential must agree to use 2 adequate forms of barrier method contraception (eg, latex condom AND intrauterine device or a diaphragm) to avoid pregnancy while in the study; 4. On a stable dose (Greater than or equal to 10 weeks at the same dose) of metformin monotherapy (Less than or equal to 1500 mg/day or maximum tolerated dose), have an HbA1c greater than or equal to 7.0% and less than or equal to 10.5%; or On metformin (less than or equal to 1500 mg/day) and 1 other antidiabetic agent (excluding TZD, insulin, or incretin therapies [DPP4 inhibitors and GLP1 analogues]) and have an HbA1c greater than or equal to 6.8% and less than or equal to 10.0%; or Not on antidiabetic therapy (for at least 3 months prior to Visit 1) or have not been on a stable dose of metformin monotherapy for 10 weeks and have an HbA1c greater than or equal to 8.0% and less than or equal to 11.0%. 1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia; 2. History or presence of alcoholism or drug abuse within the 2 years prior to dosing; 3. Typical consumption of greater than or equal to 10 drinks of alcohol weekly; 4. Presence of any of the following conditions: Significant renal impairment (glomerular filtration rate less than 60 mL/min); Diabetic gastroparesis; Active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, or symptomatic gallbladder disease; 5. Fasting plasma glucose/blood glucose greater than 240 mg/dL (13.3 mmol/L) at Visit 3 (Week 2) (1 laboratory retest permitted); 6. Body mass index less than or equal to 20 kg/m2 and greater than or equal to 48 kg/m2; 7. Systolic blood pressure &lt;100 mmHg or &gt;160 mmHg and diastolic blood pressure &lt;50 mmHg or &gt;100 mmHg at Visit 3 (Note: medication to control blood pressure is allowed and should be optimized and stabilized prior to Visit 3); 8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 X the upper limit of normal (ULN) (1 laboratory retest permitted); 9. Creatine phosphokinase (CPK) greater than 2 X the ULN (if not explained by muscular trauma or exercise) (1 laboratory retest permitted); 10. Serum creatinine &gt;1.5 mg/dL for males (132.6 μmol/L) and 1.4 mg/dL for females (123.8 μmol/L); 11. Fasting triglycerides (TG) &gt;600 mg/dL (6.78 mmol/L) at Visit 3 (Week 2) (Note: diet/exercise and lipidlowering medication to control elevated TG is allowed; medications should be optimized and stabilized prior to Visit 3); 12. Treatment with pioglitazone or rosiglitazone within the previous 10 weeks (Visit 1); treatment with incretin therapy (DPP4 inhibitors or GLP1 analogues) within the previous 4 weeks (Visit 1); 13. Treatment with any type of insulin (ie, injected or inhaled) within the previous 3 months; 14. Must meet other laboratory and Medical History clinical criteria. Please contact recruitment center for referrals</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Metformin</keyword>
</DOC>